University of Cincinnati announces new Center for Public Health
Business Announcement
Updates every hour. Last Updated: 15-Jun-2026 13:15 ET (15-Jun-2026 17:15 GMT/UTC)
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.
The National Comprehensive Cancer Network and NCCN Foundation select five Young Investigator Award recipients from Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, O'Neal Comprehensive Cancer Center at UAB, Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, and The University of Texas MD Anderson Cancer Center.